Adam Stys, MD
Interventional Cardiology · Sioux Falls, SDNPI 1083656821
Payments from drug & device makers
Across 308 payments — averaging $502.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endotronix, Inc.$148K
- Abbott$2K
- Medtronic$1K
- Abiomed$903
- Acist Medical Systems, Inc.$546
- Johnson & Johnson$473
- plus $2K from 29 others
What the payments were for
- Travel & lodging$1,09015%
- Food & beverage$6,23385%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endotronix, Inc. | 1 | $147,551 |
| Abbott | 28 | $2,134 |
| Medtronic(2 entities) | 49 | $1,186 |
| Abiomed | 19 | $903 |
| Acist Medical Systems, Inc. | 3 | $546 |
| Johnson & Johnson | 59 | $473 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $401 |
| E.r. Squibb & Sons, L.L.C. | 24 | $298 |
| AstraZeneca | 17 | $240 |
| Edwards Lifesciences | 14 | $144 |
| Boston Scientific | 6 | $135 |
| Regeneron Healthcare Solutions, Inc. | 7 | $133 |
| Chiesi USA, Inc. | 5 | $64 |
| Amarin Pharma, Inc. | 5 | $63 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Pfizer | 3 | $58 |
| Actelion Pharmaceuticals US, Inc. | 4 | $54 |
| Alnylam Pharmaceuticals Inc. | 2 | $54 |
| Cardiovascular Systems Inc. | 2 | $42 |
| Asahi Intecc USA, Inc. | 2 | $39 |
| Reflow Medical Inc | 1 | $35 |
| Shockwave Medical, Inc | 2 | $32 |
| Amgen | 2 | $28 |
| Philips North America LLC | 1 | $28 |
| Portola Pharmaceuticals, LLC | 2 | $25 |
| Lundbeck LLC | 2 | $24 |
| United Therapeutics Corporation | 2 | $22 |
| BD | 1 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,082
- HD-IVUS$340
- Impella$279
- CardioMEMS HF System$205
- COREVALVE EVOLUT R$138
- Xience Sierra Coronary Stent System$132
- CVI SYSTEMS$122
- Resolute$101
- Euphora$101
How this compares
Too few interventional cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 815 | $719,161 |
| XareltoRivaroxaban | 391 | $328,287 |
| Repatha SureclickEvolocumab | 98 | $60,796 |
| Praluent PenAlirocumab | 68 | $34,017 |
| BrilintaTicagrelor | 60 | $32,078 |
| EntrestoSacubitril/Valsartan | 28 | $28,489 |
| MultaqDronedarone Hcl | 15 | $14,119 |
| Metoprolol Succinate | 992 | $11,748 |
| JardianceEmpagliflozin | 17 | $11,149 |
| Ranolazine ErRanolazine | 70 | $9,306 |
| Repatha SyringeEvolocumab | 16 | $8,271 |
| Rosuvastatin Calcium | 585 | $7,361 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 193 | $6,857 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $6,188 |
| Ezetimibe | 179 | $6,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $719,161815 claims |
| Johnson & JohnsonXarelto | $473 | $328,287391 claims |
| AstraZenecaBrilinta | $240 | $32,07860 claims |
| Sanofi-aventis U.S. LLCMultaq | $12 | $14,11915 claims |
| Boehringer IngelheimJardiance | $11 | $11,14917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Sioux Falls
- Tomasz StysSioux Falls$678K
- John WagenerSioux Falls$123K
- Thomas WaterburySioux Falls$13K
- Sean HalliganSioux Falls$12K
- Marian PetraskoSioux Falls$4K
- Raymond AllenSioux Falls$885
- Jeremy ScottSioux Falls$344
- Tarek MahrousSioux Falls$178
- Joseph TumaRapid City$154K
- Thomas WilsonRapid City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.